Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902048 | 0.83 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3926008 | 0.82 | TMEM97 (0.42) | TRPM8P2RX3P2RX2 | |
| SCHEMBL6796558 | 0.82 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3173765 | 0.81 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL341372 | 0.80 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL377928 | 0.79 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL6651104 | 0.78 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3938891 | 0.78 | MAOA (0.40) | TRPM8MAOAMAOBALDH1A1XBP1 | |
| SCHEMBL8933069 | 0.76 | FABP5 (0.42) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL1869833 | 0.76 | FABP5 (0.50) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750005-B2 | Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1599480-B1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7390814-B2 | Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1599480-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004072076-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DPYD, TYMP, DHPS | KMT2A 4378/4885FABP5 2798/4885FABP7 3687/4885 |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, TYMP, G6PD | KMT2A 4317/4885FABP5 2669/4885FABP7 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.